利索-全球专利检索

  1. 登录
  2. 注册

搜索结果

54 条记录 (耗时 0.019 秒)

    LERCANIDIPINE CAPSULES
    1.
    发明公开
    LERCANIDIPINE CAPSULES 审中-公开
    乐卡地平胶囊

    公开(公告)号：EP1807059A1

    公开(公告)日：2007-07-18

    申请号：EP05794809.3

    申请日：2005-10-05

    申请人： Recordati Ireland Limited ,  RECORDATI INDUSTRIA CHIMICA E FARMACEUTICA S.p.a.

    发明人： LEONARDI, Amedeo ,  BERLATI, Fabio ,  PONTELLO, Lino

    IPC分类号： A61K9/48 ,  A61K31/4422

    CPC分类号： A61K31/455 ,  A61K9/4858 ,  A61K9/4866 ,  A61K31/4422

    摘要： A modified release pharmaceutical composition comprises lercanidipine dissolved in a waxy substance comprising a polyalcohol fatty acid ester, the solution being contained within a pharmaceutically acceptable capsule. Preferably the polyalcohol fatty acid ester is a polyethylene glycol ester, a polypropylene glycol ester, a fatty acid glyceride or a mixture of two or more thereof. Most preferably, the polyalcohol fatty acid ester is a mixture of mono-, di- and triglycerides and polyethylene glycol mono- and diesters. Oral administration of the modified release pharmaceutical compositions to a patient has been shown to result in a mean lercanidipine plasma concentration of greater than 0.5 ng/ml for 24 hours after administration.

    LERCANIDIPINE SALTS
    2.
    发明公开
    LERCANIDIPINE SALTS 有权

    公开(公告)号：EP1799644A1

    公开(公告)日：2007-06-27

    申请号：EP05776228.8

    申请日：2005-08-22

    申请人： Recordati Ireland Limited ,  RECORDATI INDUSTRIA CHIMICA E FARMACEUTICA S.p.a.

    发明人： LEONARDI, Amedeo ,  MOTTA, Gianni ,  VON RAUMER, Markus

    IPC分类号： C07D211/90 ,  A61K31/4422 ,  A61P9/12

    CPC分类号： C07D211/90

    摘要： The invention relates to new addition salts comprising lercanidipine and an acid counterion selected from the group consisting of: (i) inorganic acids, (ii) sulphonic acids, (iii) monocarboxylic acids, (iv) dicarboxylic acids, (v) tricarboxylic acids, and (vi) aromatic sulphonimides, with the proviso that said acid counterion is not hydrochloric acid. In particular, both amorphous and crystalline salts of lercanidipine with benzenesulphonic and naphthalene- 1,5-disulphonic acids are disclosed, as are amorphous salts of lercanidipine with several other acid counterions.

    摘要翻译： （i）无机酸，（ii）磺酸，（iii）一元羧酸，（iv）二元羧酸，（v）三元羧酸， 和（vi）芳族磺酰亚胺，条件是所述酸抗衡离子不是盐酸。 具体而言，公开了苯基磺酸和萘-1,5-二磺酸的乐卡地平的无定形盐和结晶盐，以及具有几种其他酸抗衡离子的乐卡地平的无定形盐。

    AMORPHOUS LERCANIDIPINE HYDROCHLORIDE
    3.
    发明公开
    AMORPHOUS LERCANIDIPINE HYDROCHLORIDE 审中-公开
    非晶态盐酸大戟胺

    公开(公告)号：EP1856051A1

    公开(公告)日：2007-11-21

    申请号：EP06723128.2

    申请日：2006-02-24

    申请人： Recordati Ireland Limited ,  RECORDATI INDUSTRIA CHIMICA E FARMACEUTICA S.p.a.

    发明人： LEONARDI, Amedeo ,  MOTTA, Gianni ,  BERLATI, Fabio

    IPC分类号： C07D211/90 ,  A61K31/435 ,  A61P9/12

    摘要： The invention provides a substantially pure amorphous lercanidipine hydrochloride having a purity of at least 95% pure, preferably at least about 97% pure, more preferably at least about 99% pure, and still more preferably at least about 99.5% pure. The invention further relates to methods of preparing substantially pure amorphous lercanidipine, as well as methods of providing rapid relief from hypertension by administering the substantially pure amorphous lercanidipine hydrochloride of the present invention to a patient in need of such treatment.

    摘要翻译： 本发明提供纯度至少95％，优选至少约97％纯，更优选至少约99％纯，并且还更优选至少约99.5％纯度的基本上纯的无定形乐卡地平盐酸盐。 本发明进一步提供了制备基本上纯的无定形乐卡地平的方法以及含有基本上纯的无定形乐卡地平的药物组合物。